An increasing understanding of the immunopathogenesis of rheumatoid arthritis and advances in biotechnology have lead to the therapeutic application of immune-specific interventions. The complexity of this disorder has generated numerous investigations using a wide range of biologic interventions. This article presents the current and potential targets for such biopharmaceutical agents and discusses their utility in rheumatoid arthritis.
|Original language||English (US)|
|Number of pages||20|
|Journal||Rheumatic Disease Clinics of North America|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas